Aigen Investment Management’s Edwards Lifesciences EW Stock Holding History

Aigen Investment Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$315K	Buy	+3,928	New	+$324K	0.08%	320
2025 Q4	–	Sell	-6,408	Closed	-$498K	–	709
2025 Q3	$498K	Sell	6,408 -8,624	-57%	-$674K	0.08%	400
2025 Q2	$1.18M	Sell	15,032 -9,058	-38%	-$676K	0.16%	203
2025 Q1	$1.75M	Buy	+24,090	New	+$1.72M	0.28%	100
2024 Q2	–	Sell	-4,532	Closed	-$433K	–	855
2024 Q1	$433K	Buy	+4,532	New	+$381K	0.09%	321
2023 Q1	–	Sell	-98,859	Closed	-$7.38M	–	680
2022 Q4	$7.38M	Buy	+98,859	New	+$7.62M	1.04%	16
2022 Q1	–	Sell	-10,042	Closed	-$1.27M	–	711
2021 Q4	$1.27M	Buy	+10,042	New	+$1.17M	0.08%	341
2021 Q2	–	Sell	-3,010	Closed	-$252K	–	554
2021 Q1	$252K	Buy	+3,010	New	+$254K	0.03%	469
2020 Q4	–	Sell	-3,420	Closed	-$273K	–	849
2020 Q3	$273K	Sell	3,420 -15,838	-82%	-$1.24M	0.03%	568
2020 Q2	$1.33M	Sell	19,258 -16,199	-46%	-$1.15M	0.17%	177
2020 Q1	$2.23M	Buy	35,457 +34,743	+4,866%	+$2.51M	0.3%	76
2019 Q4	$56K	Buy	+714	New	+$55.8K	0.01%	794

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Aigen Investment Management's EW Position: Q1 2026 in Review

Aigen Investment Management opened a new position in Edwards Lifesciences (EW) in Q1 2026: 3,928 shares worth $315K. The stake represents 0.08% of the portfolio and ranks #320 among its holdings. This is a return to the name: Aigen Investment Management previously reported a position in EW as recently as Q3 2025.

Aigen Investment Management first reported a position in EW in Q4 2019 and has held it in 12 quarters since. The position peaked at $7.38M in Q4 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Aigen Investment Management held 3,928 shares of Edwards Lifesciences worth $315K as of Q1 2026.
Edwards Lifesciences was a new Aigen Investment Management position in Q1 2026.
Edwards Lifesciences made up 0.08% of Aigen Investment Management's portfolio in Q1 2026, its #320 holding.
Aigen Investment Management first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 12 quarters since.
Aigen Investment Management's Edwards Lifesciences position peaked at $7.38M in Q4 2022.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.